Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01339962

Enrollment

1073

Registered

2011-04-21

Start date

2011-04-30

Completion date

2012-04-30

Last updated

2014-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma

Keywords

Metastatic renal cell carcinoma

Brief summary

Non-interventional study. Data obtained by patient chart reviews. Retrospective analysis of progression free survival, time to treatment failure and overall survival in a national cohort of patients with metastatic renal cell carcinoma treated in Denmark from 2006-2010 Safety, prognostic factors, predictive factors and co-morbidity assessed by Charlson Comorbidity Index. The following drugs will be evaluated: Sunitinib, Sorafenib, Temsirolimus, Everolimus, Aldesleukin, Interferon-alfa-2b.

Detailed description

No sampling. All eligible patients will be included.

Interventions

OTHERNon-interventional

Non-interventional (retrospective chart reviews)

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Metastatic renal cell carcinoma

Exclusion criteria

None

Design outcomes

Primary

Measure	Time frame
Overall survival from initiation of first systemic anticancer therapy	8 months
Progression free survival from initiation of each systemic anticancer therapy separately	8 months
Time to treatment failure from initiation of each systemic anticancer therapy separately	8 months

Secondary

Measure	Time frame
Co-morbidity assessed by Charlson Comorbidity Index	8 months
Combined PFS and OS on sequential treatment	8 months
Prognostic factors at baseline associated with efficacy (PFS) of each systemic anticancer therapy and overall survival	8 months
Assessment of prognostic factors and overall survival for patients not receiving systemic therapy	8 months
Assessment of first line immunotherapy´s effect on second line targeted therapy	8 months
Serious Adverse Events: Defined as AEs leading to dose adjustment, treatment interruption/ cessation or death.	8 months
Predictive factors	8 months

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026